Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors
Paediatr Drugs. 2023 Aug 28. doi: 10.1007/s40272-023-00585-8. Online ahead of print.ABSTRACTThe number of childhood cancer survivors is increasing rapidly. According to American Association for Cancer Research, there are more than 750,000 childhood cancer survivors in the United States and Europe. As the number of childhood cancer survivors increases, so does cancer treatment-related cardiac dysfunction (CTRCD), leading to heart failure (HF). It has been reported that childhood cancer survivors who received anthracyclines are 15 times more likely to have late cancer treatment-related HF and have a 5-fold higher risk of dea...
Source: Paediatric Drugs - August 28, 2023 Category: Pediatrics Authors: Bibhuti Das Source Type: research
Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors
Paediatr Drugs. 2023 Aug 28. doi: 10.1007/s40272-023-00585-8. Online ahead of print.ABSTRACTThe number of childhood cancer survivors is increasing rapidly. According to American Association for Cancer Research, there are more than 750,000 childhood cancer survivors in the United States and Europe. As the number of childhood cancer survivors increases, so does cancer treatment-related cardiac dysfunction (CTRCD), leading to heart failure (HF). It has been reported that childhood cancer survivors who received anthracyclines are 15 times more likely to have late cancer treatment-related HF and have a 5-fold higher risk of dea...
Source: Paediatric Drugs - August 28, 2023 Category: Pediatrics Authors: Bibhuti Das Source Type: research
The Future of Advanced Therapies for Pediatric Crohn's Disease
Paediatr Drugs. 2023 Aug 23. doi: 10.1007/s40272-023-00590-x. Online ahead of print.ABSTRACTPediatric Crohn's disease commonly presents with moderate-to-severe intestinal inflammation with a greater risk of complications if remission is not achieved. Anti-tumor necrosis factor therapies have offered the possibility of deep and durable remission; however, many children do not respond or no longer respond over time. Further, some children do not require broader systemic immunosuppression to achieve remission and are better served by an alternative treatment strategy. Proper utilization of advanced biologic and small-molecule...
Source: Paediatric Drugs - August 23, 2023 Category: Pediatrics Authors: Julie Gallagher Joel R Rosh Benjamin Sahn Source Type: research
The Future of Advanced Therapies for Pediatric Crohn's Disease
Paediatr Drugs. 2023 Aug 23. doi: 10.1007/s40272-023-00590-x. Online ahead of print.ABSTRACTPediatric Crohn's disease commonly presents with moderate-to-severe intestinal inflammation with a greater risk of complications if remission is not achieved. Anti-tumor necrosis factor therapies have offered the possibility of deep and durable remission; however, many children do not respond or no longer respond over time. Further, some children do not require broader systemic immunosuppression to achieve remission and are better served by an alternative treatment strategy. Proper utilization of advanced biologic and small-molecule...
Source: Paediatric Drugs - August 23, 2023 Category: Pediatrics Authors: Julie Gallagher Joel R Rosh Benjamin Sahn Source Type: research
The Future of Advanced Therapies for Pediatric Crohn's Disease
Paediatr Drugs. 2023 Aug 23. doi: 10.1007/s40272-023-00590-x. Online ahead of print.ABSTRACTPediatric Crohn's disease commonly presents with moderate-to-severe intestinal inflammation with a greater risk of complications if remission is not achieved. Anti-tumor necrosis factor therapies have offered the possibility of deep and durable remission; however, many children do not respond or no longer respond over time. Further, some children do not require broader systemic immunosuppression to achieve remission and are better served by an alternative treatment strategy. Proper utilization of advanced biologic and small-molecule...
Source: Paediatric Drugs - August 23, 2023 Category: Pediatrics Authors: Julie Gallagher Joel R Rosh Benjamin Sahn Source Type: research
The Future of Advanced Therapies for Pediatric Crohn's Disease
Paediatr Drugs. 2023 Aug 23. doi: 10.1007/s40272-023-00590-x. Online ahead of print.ABSTRACTPediatric Crohn's disease commonly presents with moderate-to-severe intestinal inflammation with a greater risk of complications if remission is not achieved. Anti-tumor necrosis factor therapies have offered the possibility of deep and durable remission; however, many children do not respond or no longer respond over time. Further, some children do not require broader systemic immunosuppression to achieve remission and are better served by an alternative treatment strategy. Proper utilization of advanced biologic and small-molecule...
Source: Paediatric Drugs - August 23, 2023 Category: Pediatrics Authors: Julie Gallagher Joel R Rosh Benjamin Sahn Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
CONCLUSION: While in patients ventilated < 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzodiazepine infusions.PMID:37550522 | DOI:10.1007/s40272-023-00587-6 (Source: Paediatric Drugs)
Source: Paediatric Drugs - August 7, 2023 Category: Pediatrics Authors: Reuth Nir Francesca Sperotto Manasee Godsay Minmin Lu John N Kheir Source Type: research
